Catheter Precision, Inc. (VTAK) Income Statement
VTAK 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVTAK revenue and net income
Where VTAK's revenue goes
2025Each bar shows an amount and its share of revenue. VTAK kept −2,098.0% of revenue as net income.
VTAK profit margins
VTAK growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +95.0% | +288.2% | −28.6% | — |
| Gross profit | +100.0% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VTAK quarterly EPS vs estimates
Catheter Precision beat the analyst EPS estimate in 0 of the last 6 quarters. Next report: November 12, 2026.
VTAK income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $819,000 | $420,000 | $442,000 | $14,000 | $22,000 | $4.4M | $7.2M | $6.3M | $5.9M | $6.0M |
| Cost of revenue | $63,000 | $42,000 | $30,000 | $161,000 | $1.6M | $5.5M | $8.8M | $4.2M | $4.2M | $3.1M |
| Gross profit | $756,000 | $378,000 | $412,000 | −$147,000 | −$1.5M | −$1.1M | −$1.7M | $2.1M | $1.7M | $2.8M |
| Research & development | $862,000 | $272,000 | $475,000 | $6.4M | $12.3M | $9.0M | $4.5M | $2.8M | $4.5M | $1.7M |
| Sales, general & admin | $12.1M | $11.3M | $17.1M | $3.5M | $15.5M | $26.0M | $51.5M | $30.4M | — | — |
| Total operating expenses | $12.9M | $11.6M | $78.5M | $26.8M | $27.7M | $35.0M | $56.1M | $33.2M | $19.5M | $7.0M |
| Operating income | −$12.2M | −$11.2M | −$78.1M | −$27.0M | −$29.3M | −$36.1M | −$57.7M | −$31.2M | −$17.8M | −$4.2M |
| Interest income | $34,000 | $81,000 | $347,000 | $0 | — | $129,000 | $1.0M | — | — | — |
| Interest expense | $281,000 | $91,000 | $0 | $3.1M | $10,000 | $108,000 | $250,000 | $14,000 | $4,000 | $3,000 |
| Income before taxes | −$19.5M | −$13.5M | −$70.6M | −$26.9M | −$27.3M | −$36.0M | −$56.9M | −$30.8M | −$17.8M | −$4.2M |
| Income taxes | −$1.8M | $3.1M | $60.6M | $3,000 | $4,000 | $7,000 | $15,000 | $10,000 | $1,000 | $1,000 |
| Net income | −$17.2M | −$16.6M | −$70.6M | −$26.9M | −$25.1M | −$36.0M | −$57.0M | −$30.8M | −$17.8M | −$4.2M |
| EBITDA | −$17.1M | −$11.3M | −$15.1M | −$22.4M | −$27.7M | −$33.7M | −$56.0M | −$30.5M | −$17.5M | −$4.1M |
| EPS (diluted) | −$9.88 | −$213.77 | −$39.23 | −$21.46 | −$5.66 | −$7.85 | −$4.34 | −$2.81 | — | — |
| Gross margin | 92.3% | 90.0% | 93.2% | −1,050.0% | −6,990.9% | −24.4% | −22.9% | 32.8% | 29.0% | 47.5% |
| Operating margin | −1,487.3% | −2,676.9% | −17,674.0% | −192,578.6% | −133,027.3% | −818.6% | −801.9% | −498.0% | −302.6% | −70.2% |
| Net margin | −2,098.0% | −3,962.6% | −15,966.5% | −191,892.9% | −113,954.5% | −818.3% | −791.2% | −492.8% | −302.6% | −70.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $432,000 | $238,000 | $226,000 | $212,000 | $143,000 | $149,000 | $96,000 | $93,000 | $82,000 | $128,000 | $133,000 |
| Cost of revenue | $921,000 | $42,000 | $20,000 | $18,000 | $14,000 | $11,000 | $11,000 | $10,000 | $16,000 | $5,000 | $7,000 | $6,000 |
| Gross profit | $98,000 | $390,000 | $218,000 | $208,000 | $198,000 | $132,000 | $138,000 | $86,000 | $77,000 | $77,000 | $121,000 | $127,000 |
| Research & development | $142,000 | $149,000 | $328,000 | $276,000 | $155,000 | $103,000 | $91,000 | $63,000 | $81,000 | $37,000 | $11,000 | $112,000 |
| Sales, general & admin | $3.9M | $2.6M | $2.8M | $3.0M | $2.9M | $3.5M | $3.1M | $2.9M | $2.7M | $2.7M | $2.7M | $2.7M |
| Total operating expenses | $4.1M | $2.7M | $3.1M | $3.2M | $3.0M | $3.6M | $3.2M | $2.9M | $2.8M | $2.7M | $2.7M | $2.9M |
| Operating income | −$4.0M | −$2.3M | −$2.9M | −$3.0M | −$2.8M | −$3.5M | −$3.1M | −$2.9M | −$2.7M | −$2.6M | −$2.6M | −$2.7M |
| Interest income | $4,000 | $2,000 | $3,000 | $10,000 | $3,000 | $18,000 | $34,000 | $7,000 | $2,000 | $30,000 | $72,000 | $87,000 |
| Interest expense | $204,000 | $119,000 | $82,000 | $83,000 | $67,000 | $49,000 | $51,000 | $32,000 | $5,000 | $3,000 | — | $0 |
| Income before taxes | −$3.6M | −$1.9M | −$6.1M | −$2.3M | −$6.4M | −$4.8M | −$2.5M | −$4.1M | −$4.2M | −$2.7M | −$669,000 | −$1.9M |
| Income taxes | $312,000 | $175,000 | −$214,000 | $78,000 | −$950,000 | −$724,000 | $3.1M | −$4.1M | — | −$30,000 | −$72,000 | −$87,000 |
| Net income | −$3.3M | −$1.7M | −$5.3M | −$2.3M | −$5.5M | −$4.0M | −$5.6M | −$4.1M | −$4.2M | −$2.7M | −$669,000 | −$1.9M |
| EBITDA | −$3.0M | −$1.5M | −$5.5M | −$1.7M | −$5.8M | −$4.2M | −$1.9M | −$3.6M | −$3.7M | −$2.2M | −$152,000 | −$1.4M |
| EPS (diluted) | −$0.92 | −$1.39 | — | −$1.70 | −$5.93 | −$0.36 | −$1.35 | −$38.19 | −$105.83 | −$68.40 | −$2.80 | −$0.28 |
| Gross margin | 9.6% | 90.3% | 91.6% | 92.0% | 93.4% | 92.3% | 92.6% | 89.6% | 82.8% | 93.9% | 94.5% | 95.5% |
| Operating margin | −388.1% | −536.6% | −1,204.2% | −1,336.7% | −1,338.7% | −2,416.8% | −2,047.7% | −2,978.1% | −2,921.5% | −3,190.2% | −2,028.9% | −2,052.6% |
| Net margin | −323.4% | −391.2% | −2,242.0% | −1,037.2% | −2,574.5% | −2,828.7% | −3,777.2% | −4,291.7% | −4,537.6% | −3,262.2% | −522.7% | −1,448.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VTAK's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VTAK financial results
In fiscal year 2025 (ended December 31, 2025), Catheter Precision reported revenue of $0.8 million, up 95.0% from the year before. It had a net loss of $17.2 million, a net profit margin of −2,098.0%. Diluted earnings per share came to −$9.88. Over five years revenue grew at an average rate of −28.6% a year.
See the VTAK stock overview for the latest quote and news, or the VTAK chart for price history and technical indicators.
VTAK income statement FAQ
What is Catheter Precision's annual revenue?
Catheter Precision reported total revenue of $0.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 95.0% from $0.4 million the previous year.
Is Catheter Precision profitable?
No. Catheter Precision reported a net loss of $17.2 million in fiscal 2025, a net profit margin of −2,098.0%; its operating margin was −1,487.3%.
What is Catheter Precision's gross margin?
Catheter Precision's gross margin was 92.3% in fiscal 2025: for every $100 of revenue, Catheter Precision kept $92 after the direct cost of its products and services.
How much does Catheter Precision spend on research and development?
Catheter Precision spent $0.9 million on research and development in fiscal 2025, 105.3% of revenue.
How fast is Catheter Precision growing?
Revenue grew −28.6% a year on average over the last five fiscal years, from $4.4 million to $0.8 million.
What are Catheter Precision's earnings per share?
Catheter Precision earned $-9.88 per diluted share in fiscal 2025, compared with $-213.77 a year earlier.
When will Catheter Precision report its next earnings?
Catheter Precision is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Catheter Precision's fiscal year end?
Catheter Precision's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.